# Therapeutic Artifact Consistency Audit V52

Date: 2026-07-10

Status: synthesis QA. This document adds no evidence and changes no verdict. It
checks whether the major V52 therapeutic artifacts state the same route ranking,
validation priority, and target boundary.

## Artifacts Checked

- `docs/reports/THERAPEUTIC_PATH_V52.md`
- `docs/reports/THERAPEUTIC_PATH_SUMMARY_CARD_V52.md`
- `docs/reports/THERAPEUTIC_TARGET_EVIDENCE_MATRIX_V52.tsv`
- `docs/reports/THERAPEUTIC_REOPEN_CHECKLIST_V52.tsv`
- `docs/validation/MEDICAL_TEAM_THERAPEUTIC_DATA_REQUEST_V52.md`
- `docs/validation/MONITORING_VALIDATION_DECISION_TREE_V52.md`
- `docs/validation/THERAPEUTIC_VALIDATION_HANDOFF_V52.md`

## Audit Checks

| check | result | note |
|---|---|---|
| Monitoring / stratification is the first impact route | pass | Main report, summary card, matrix, validation handoff, request packet, and decision tree all preserve this. |
| No current intervention-grade target | pass | Main report, summary card, matrix, reopen checklist, and skeptic checklist all keep targets below promotion. |
| chr1 is the closest target-development handoff, not a target | pass | Main report, matrix, request packet, chr1 data spec, experiment blueprint, and reopen checklist all agree. |
| Structure context does not rescue targets | pass | Main report, summary card, structure QA, no-go table, and reopen checklist all preserve this boundary. |
| Restored OpenGWAS does not reopen discovery | pass | Main report and bounded rerun manifest agree that only targeted reruns/polish are allowed. |
| Gafson/Karolinska are validation routes, not tuning data | pass | Validation handoff, request packet, and decision tree all state frozen V42/V44 harness only. |
| Reopen TSV omits live monitoring route | intentional | The reopen checklist is scoped to closed or conditional leads; monitoring is handled by validation handoff and decision tree. |

## Term Counts Used As Sanity Check

The audit scanned the checked artifacts for key terms. Counts are not evidence;
they are a quick consistency check.

| artifact | monitoring | stratification | intervention-grade | Gafson | Karolinska | chr1 |
|---|---:|---:|---:|---:|---:|---:|
| `THERAPEUTIC_PATH_V52.md` | 7 | 3 | 3 | 4 | 3 | 17 |
| `THERAPEUTIC_PATH_SUMMARY_CARD_V52.md` | 4 | 1 | 1 | 2 | 2 | 5 |
| `THERAPEUTIC_TARGET_EVIDENCE_MATRIX_V52.tsv` | 2 | 1 | 1 | 1 | 1 | 3 |
| `THERAPEUTIC_REOPEN_CHECKLIST_V52.tsv` | 0 | 0 | 0 | 0 | 0 | 1 |
| `MEDICAL_TEAM_THERAPEUTIC_DATA_REQUEST_V52.md` | 11 | 1 | 0 | 0 | 0 | 8 |
| `MONITORING_VALIDATION_DECISION_TREE_V52.md` | 6 | 1 | 0 | 1 | 1 | 1 |
| `THERAPEUTIC_VALIDATION_HANDOFF_V52.md` | 5 | 1 | 0 | 4 | 4 | 1 |

The zero monitoring count in `THERAPEUTIC_REOPEN_CHECKLIST_V52.tsv` is expected
because that artifact covers reopen gates, not the live validation route.

## Verdict

No V52 artifact inconsistency was found. The project-wide therapeutic message is
consistent:

1. validate the monitoring / stratification lead first;
2. do not promote any intervention-grade target now;
3. keep chr1 as the closest target-development handoff;
4. require genotype-linked cell-state direction and direction-matched
   perturbation before any target workup;
5. treat structure and restored OpenGWAS as bounded context, not rescue.

## Follow-Up

Future edits to any V52 summary, request packet, or target table should preserve
this five-point message or explicitly record the new evidence that changed it.
